Navigation Links
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
Date:6/4/2008

SAN DIEGO, June 4 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present the corporate overview on Wednesday, June 11, 2008 at 3:00 pm Eastern Time (12:00 pm Pacific Time) during the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference at the New York Palace Hotel in New York City.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts: William R. LaRue Anna Gralinska


'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
2. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
3. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
4. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
5. Antipodean Pharmaceuticals Announces FDA Acceptance of IND for MitoQ(R)
6. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
7. Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
8. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
9. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
10. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
11. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... The MCA Youth Empowerment Conference aims to bridge youths ... towards the goal for a better future for all ... smaller groups will be held after the conference with ... Healthcare, Social and Volunteerism, Women and Youth Empowerment, to ... , Young adults aged between 18-30 years that have ...
(Date:2/28/2015)... TX (PRWEB) March 01, 2015 Heart ... estimated that 10 percent of urban adult population and ... form of heart diseases and 20-30 percent of them ... to heart ailments and coronary vascular diseases (CVD). , ... launched a new market research report titled “Indian Coronary ...
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 people to discover ... “The #1 block was lack of time and ... who created the Thinkubator Innovation Studio in Chicago. ... did not have enough time for innovative thinking and ... , Solutionman’s monthly “Accelerating Innovation Training” workshops address the ...
(Date:2/28/2015)... Calgary, AB (PRWEB) February 28, 2015 ... and is now a distributor of the machine. The ... part of their license, like a franchise model. The ... people prevent and reverse heart disease. To buy ... Heart Fit Clinic can help individuals through this process ...
(Date:2/28/2015)... February 28, 2015 March—also known ... time to remind ourselves and others that suspected ... Atlantic NeuroSurgical Specialists (ANS). , Concussions are a ... for 75% of TBIs. There are 1.6-3.8 million ... sound benign, but it is a brain injury. ...
Breaking Medicine News(10 mins):Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3
... PHILADELPHIA, Nov. 6 The American Academy of ... members of Lippincott Williams & Wilkins (LWW) nursing ... Wolters Kluwer Health, a leading provider of information ... in medicine, nursing, allied health, and pharmacy. Academy ...
... groups pay off, study finds , FRIDAY, Nov. ... starting a walking group or creating pedestrian-friendly routes ... study has found. , At a multicultural housing ... interventions meant to increase residents, walking, including sponsoring ...
... St. Michael,s Hospital working in conjunction with EMS services, paramedics ... attempts cardiopulmonary resuscitation (CPR) can quadruple the survival rate to ... research team at Rescu ( www.rescu.ca ) have found only ... help, one of the lowest rates of bystanders helping others ...
... With 125 million Americans challenged by at least one chronic illness ... chronic illnesses, early, smart estate and financial planning can make the ... its exigencies. , WHAT : ... importance for people living with chronic illness and their advisers: ...
... Bermuda, Nov. 6 Allied World Assurance,Company Holdings, ... Allied World U.S.,Nicole Baummer, Assistant Vice President for ... Professional Lines,Claims, will be speaking at this year,s ... held in Chicago, Illinois,November 11-13, 2009. , ...
... tables cleaned less often than toilet seats, study finds ... of restrooms aboard cruise ships raises the risk of ... Norovirus causes about 95 percent of acute gastroenteritis outbreaks ... norovirus outbreaks occurred on 66 ships monitored by the ...
Cached Medicine News:Health News:Seven LWW Nursing Editors Recognized as Leaders by American Academy of Nursing 2Health News:Seven LWW Nursing Editors Recognized as Leaders by American Academy of Nursing 3Health News:Less than 1 in 3 Toronto bystanders who witness a cardiac arrest try to help: Study 2Health News:Less than 1 in 3 Toronto bystanders who witness a cardiac arrest try to help: Study 3Health News:Chronic Illness: Estate Planning 2Health News:Chronic Illness: Estate Planning 3Health News:Chronic Illness: Estate Planning 4Health News:Allied World's Nicole Baummer and Marjorie Thompson to Speak at PLUS International Conference 2Health News:Allied World's Nicole Baummer and Marjorie Thompson to Speak at PLUS International Conference 3Health News:Poor Restroom Cleaning Causes Cruise-Ship Sickness 2
(Date:2/27/2015)... 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... study published in the Proceedings of the ... that showed when ibrutinib (IMBRUVICA ® ) was ... suppression of tumor growth was enhanced suggesting a ... hematologic cancers and solid tumors with the combination. ...
(Date:2/27/2015)... , Feb. 27, 2015 Securities lawyers at ... of Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP ) ... share. Concerned SLXP investors are encouraged to contact attorney ... The investigation focuses upon the shareholder value of ... shareholders would receive only $158.00 per share in cash. ...
(Date:2/27/2015)... Feb. 27, 2015  Boston Scientific Corporation (NYSE: ... Barclays 2015 Annual Healthcare Conference on March 10 in ... Dan Brennan , executive vice president and chief financial ... Relations, will participate in a 25-minute question and answer ... approximately 1:05 p.m. ET. Following a 5-minute break, a ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2
... 6, 2012 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ... permanent J-code, for KRYSTEXXA® (pegloticase) became available on January ... the Centers for Medicare and Medicaid Services (CMS) and ... prescribers of KRYSTEXXA, the first and only U.S. Food ...
...  Endo Pharmaceuticals (Nasdaq: ENDP ) announced today ... with U.S.-based BioDelivery Sciences International (Nasdaq: BDSI ... is a transmucosal form of buprenorphine, a partial mu-opiate ... BEMA Buprenorphine is currently in phase III trials for ...
Cached Medicine Technology:Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 2Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 3Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 4Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 5Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 6Endo Pharmaceuticals and BioDelivery Sciences International Sign Licensing Agreement for BEMA Buprenorphine 2
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
... solution tricompartmental total knee prosthesis stems from ... State-of-the-art design and manufacturing technologies have been ... function as well as a favorable pressure ... to keep wear to a minimum. The ...
... Foundation PS knee offers a femoral option and ... action that engages at 60 degrees of flexion ... and allow for 130 degrees of flexion. Femoral ... with prominent lateral flare. The constrained tibial insert ...
... BioPro Total Knee system ... anatomical replacement of all ... knee joint, while preserving ... Posterior Ligaments, bone stock, ...
Medicine Products: